IndoTBseq-sc-5161
IndoTBseq
Whole genome sequencing (WGS) has been shown to be a potential tool for reliable prediction of the drug susceptibility phenotype within a clinically relevant timeframe. In this study, we will apply WGS to predict drug resistance in Indonesia, which has the second-highest TB burden in the world. In Indonesia, diagnosis of drug-resistant TB is challenging as M. tuberculosis culture is not routinely performed, and DST is only available in certain reference laboratories. To date, the contribution and concordance of phenotypic and genotypic drug-susceptibility testing in Indonesia is unknown. This study will provide data through WGS on the resistance-conferring mutations to first and second-line TB drugs in Indonesia, their distribution among different M. tuberculosis lineages, and concordance with phenotypic DST, using 150 consecutive isolates collected from MDR-TB patients in Bandung, Indonesia. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
Study objectives: 1) Determine the role of whole-genome sequencing (WGS) in drug susceptibility testing (DST) of M. tuberculosis; 2) Evaluate potential causes of discrepancies between genotypic and phenotypic DST results; 3) Use WGS to investigate the population structure of resistant M. tuberculosis.